The new protein carrier was developed on the basis of recombinant RNA phage Qbeta capsid. C-terminal UGA extension of the short form of Qbeta coat, so-called A1 extension, served as a target for presentation of foreign peptides on the outer surface of mosaic Qbeta particles. In conditions of enhanced UGA suppression, the proportion of A1-extended to short coats in mosaic particles dropped from 48% to 14%, with an increase of the length of A1 extension. A model insertion, short preS1 epitope 31-DPAFR-35 of hepatitis B surface antigen, demonstrated superficial location on the mosaic Qbeta particles and ensured specific antigenicity and immunogenicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0014-5793(98)00716-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy.
Bioconjug Chem
September 2023
Department of NanoEngineering, University of California, San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
Article Synopsis
- Toll-like receptors (TLRs) are important for cancer immunotherapy as they activate the immune system, but their clinical use is limited by side effects and poor pharmacokinetics.
- Researchers developed plant virus nanoparticles (VNPs) and bacteriophage virus-like particles (VLPs) as delivery systems to improve the effectiveness of TLR agonists, specifically TLR3 and TLR7 agonists.
- The study found that conjugating the TLR7 agonist 1V209 and the TLR3 agonist poly(I:C) to VNPs/VLPs significantly enhanced immune activation, reduced tumor growth, and extended mouse survival compared to using the agonists alone.
COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response.
Front Microbiol
April 2023
Department of NanoEngineering, University of California, San Diego, La Jolla, CA, United States.
The COVID-19 pandemic caused by SARS-CoV-2 sparked intensive research into the development of effective vaccines, 50 of which have been approved thus far, including the novel mRNA-based vaccines developed by Pfizer and Moderna. Although limiting the severity of the disease, the mRNA-based vaccines presented drawbacks, such as the cold chain requirement. Moreover, antibody levels generated by these vaccines decline significantly after 6 months.
View Article and Find Full Text PDFDevelopment of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant.
Bioconjug Chem
January 2023
Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, United States.
The SARS-CoV-2 pandemic has highlighted the need for vaccines that are effective, but quickly produced. Of note, vaccines with plug-and-play capabilities that co-deliver antigen and adjuvant to the same cell have shown remarkable success. Our approach of utilizing a nitrilotriacetic acid (NTA) histidine (His)-tag chemistry with viral adjuvants incorporates both of these characteristics: plug-and-play and co-delivery.
View Article and Find Full Text PDFA single-dose Qβ VLP vaccine against S100A9 protein reduces atherosclerosis in a preclinical model.
Adv Ther (Weinh)
October 2022
Department of NanoEngineering, University of California-San Diego, La Jolla CA 92039, USA.
The standard therapy for cardiovascular disease (CVD) is the administration of statins to reduce plasma cholesterol levels, but this requires lifelong treatment. We developed a CVD vaccine candidate that targets the pro-inflammatory mediator calprotectin by eliciting antibodies against the S100A9 protein. The vaccine, based on bacteriophage Qβ virus-like particles (VLPs) displaying S100A9 peptide epitopes, was formulated as a slow-release PLGA:VLP implant by hot-melt extrusion.
View Article and Find Full Text PDFIn Vivo Fate of Cowpea Mosaic Virus In Situ Vaccine: Biodistribution and Clearance.
ACS Nano
November 2022
Department of NanoEngineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States.
Article Synopsis
- Cowpea mosaic virus (CPMV) acts as a powerful immunomodulator for cancer treatment when injected directly into tumors, enhancing the immune response to both the targeted tumor and distant sites.
- Studies show that CPMV vaccination not only works well in mouse models but also shows promising results in dogs with spontaneous tumors.
- Human testing reveals that a significant number of patients have been exposed to CPMV and other plant viruses, indicating potential immunogenicity, but CPMV is noninfectious to mammals, raising questions about its safety for use in humans.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!